Results 231 to 240 of about 798,871 (303)

Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system. [PDF]

Front Pharmacol
Chokkakula S, Guo Q, Zhang X, Bin Jumah J, Naveen B, Yang B.   +5 more
europepmc   +1 more source

Decoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles

Advanced Science, EarlyView.
Lipid nanoparticles (LNPs) enable efficient nucleic acid delivery, but their immunogenicity is a double‐edged sword. This review explores LNP‐driven innate and adaptive immunity, covering lipid components, endosomal escape, and nucleic acid sensing.
Ruimin Hu, Yin Dou, Chenwen Li, Yuying Mu, Huiying Ouyang, Wenhao Shen, Jianxiang Zhang   +6 more
wiley   +1 more source

Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database. [PDF]

Ther Adv Drug Saf
Lv B, Han J, Yu Y, Li Y.
europepmc   +1 more source

Balancing Stealth and Targetability: cCPP‐ and PEG‐Modified Liposomes for the Targeted Delivery of Anti‐HER2 Nanobodies

Advanced Science, EarlyView.
This study addresses the rapid renal clearance of anti‐HER2 nanobodies by developing specialized liposomal carriers. It details the formulation of dual modified liposomes, demonstrating how PEGylation preserves structural integrity and cell‐penetrating peptides enhance cellular interaction.
Giulia Pander, Maria del Pilar Palacios Cisneros, Clara Certa, Megan Stierli, Katharina Beck, Nicolas Färber, Lisa Blank, Fiona Tanner, Eric Mühlberg, Sabrina Wohlfart, Christian Kleist, Jörg Huwyler, Gert Fricker, Walter Mier, Philipp Uhl   +14 more
wiley   +1 more source

A Comprehensive Approach to Selection of Adverse Drug Reactions for a Drug with Conditional Marketing Authorisation in the European Union. [PDF]

Adv Ther
Hittel N, Lazarevic N, Martin A, Schorn B, Leporowski A, Zhang V, George V, van Heumen E.   +7 more
europepmc   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

Pharmacovigilance analysis and real-world adverse event profile (safety signals and product-related issues) of potassium citrate: a US FDA adverse event reporting system (FAERS) based analysis. [PDF]

Urolithiasis
Ergül RB, Gürlek IT, Yitgin Y, Ozcan SG, Özervarlı MF, Turan S, Verep S, Şenel S, Atar A, Kiremit M, Pietropaolo A, Gökçe Mİ, Somani B, Sarica K, Tefik T.   +14 more
europepmc   +1 more source

Trophic Diversity in Duckweed: Mixotrophy, More Than the Sum of its Extremes

Advanced Science, EarlyView.
In the context of rising DOC in aquatic environments, mixotrophic duckweed may impact carbon cycling by acting as either a carbon sink, as they absorb CO2 through photosynthesis, or a carbon source, as they release CO2 through respiration of absorbed DOC, which depends on DOC concentration, light availability, temperature, and other environmental ...
Zuoliang Sun, Yan Chen, Fajun Li, Xuyao Zhao, Qingxiang Han, Hongwei Hou   +5 more
wiley   +1 more source

Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase. [PDF]

Orphanet J Rare Dis
Tezel-Yalçın H, Yalçın N, Allegaert K, Erkekoğlu P.   +3 more
europepmc   +1 more source

Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium. [PDF]

Clin Cancer Res
Wessel KM, Janeway KA, Davis LE, Drezner N, Donoghue M, Helman LJ.   +5 more
europepmc   +1 more source